
Jan 8 (Reuters) - GRI Bio Inc GRI.O:
GRI BIO ANNOUNCES ADDITIONAL POSITIVE DATA FROM PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS, STRENGTHENING CLINICAL PROOF-OF-CONCEPT FOR GRI-0621
GRI BIO INC: GRI-0621 CONTINUES TO DEMONSTRATE A COMPELLING PROFILE, COMBINING FAVORABLE SAFETY AND TOLERABILITY